Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
JANXthis companyJanux Therapeutics, Inc.	$13.70	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
CGEMCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
CLDXCelldex Therapeutics, Inc.	$31.21	-6.96×	3.43×	1,204.09×	-6.97×	-99.2%	100.0%	-19160.0%	-17253.3%	-49.1%	-53.9%	-11.8%	0×	0.1×	0×	10.49×	0.0%	2	16.42	2	C
CMPXCompass Therapeutics, Inc.	$0.80	-12.79×	4.3×	0×	-12.7×	-84.0%	0.0%	0.0%	0.0%	-33.8%	-35.3%	-5.8%	0.05×	0.32×	0×	15.02×	0.0%	3	-0.29	2	C+
CTMXCytomX Therapeutics, Inc.	$2.08	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
IMNMImmunome, Inc.	$19.48	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
Peer median	—	-8.84×	3.43×	7.71×	-6.97×	-90.4%	57.4%	-29.3%	-22.8%	-33.8%	-35.3%	-11.8%	0.01×	0.39×	0×	10.49×	0.0%	2	9.54	2	—